Form 4: Soleno Therapeutics Executive Sells Shares Under 10b5-1 Trading Plan

Patricia C. Hirano, a Senior Vice President at Soleno Therapeutics, sold 3,782 shares of common stock on April 1, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 1, 2025, Patricia C. Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics Inc. (SLNO), sold 3,782 shares of common stock.
• The sale was executed at a price of $70.11 per share, resulting in a total transaction value of $265,123.02.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following the transaction, Hirano directly owns 27,036 shares of Soleno Therapeutics common stock, some of which are restricted stock units (RSUs) representing a contingent right to receive one share of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Industry Context

This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but the effect is likely to be minimal given the pre-planned nature of the transaction.

Key Dates

Keywords

Form 4, Soleno Therapeutics, SLNO, Patricia C. Hirano, Rule 10b5-1, Insider Trading, Stock Sale, Senior Vice President, Regulatory Affairs, Restricted Stock Units, RSU